{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T10:49:17Z","timestamp":1753181357017},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[1993,12,1]],"date-time":"1993-12-01T00:00:00Z","timestamp":754704000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[1993,12]]},"DOI":"10.1007\/bf00975048","type":"journal-article","created":{"date-parts":[[2005,1,19]],"date-time":"2005-01-19T10:43:33Z","timestamp":1106131413000},"page":"1281-1285","source":"Crossref","is-referenced-by-count":3,"title":["Effects of chronic brofaromine administration on biogenic amines including sulphatoxymelatonin and acid metabolites in patients with bulimia nervosa"],"prefix":"10.1007","volume":"18","author":[{"given":"Sidney H.","family":"Kennedy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce A.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory M.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine G.","family":"Ford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"d'Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1987","unstructured":"American Psychiatric Association 1987. Diagnostic and Statistical Manual of Mental Disorders (3rd ed., rev). Author, Washington, D.C.","edition":"3rd ed., rev"},{"key":"CR2","doi-asserted-by":"crossref","unstructured":"Kaye, W. H., Ballenger, J. C., Lydiard, R. B., Stuart, G. W., Laraia, M. T., O'Neil, P., Fossey, M. D., Lesser, S. and Hsu, G. CSF monoamine levels in normal-weight bulimia: Evidence for abnormal noradrenergic activity. Am. J. Psychiatry, 147:225?229.","DOI":"10.1176\/ajp.147.2.225"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1177\/070674379003500904","volume":"35","author":"D. S. Goldbloom","year":"1990","unstructured":"Goldbloom, D. S. and Garfinkel, P. E. 1990. The serotonin hypothesis of bulimia nervosa: theory and evidence. Can. J. Psychiatry, 35:741?744.","journal-title":"Can. J. Psychiatry"},{"key":"CR4","first-page":"105","volume-title":"The Biology of Feast and Famine: Relevance to Eating Disorders","author":"W. H. Kaye","year":"1992","unstructured":"Kaye, W. H. 1992. Neurotransmitter abnormalities in anorexia and bulimia nervosa. Pages 105?134.in G. H. Anderson and S. H. Kennedy (eds). The Biology of Feast and Famine: Relevance to Eating Disorders. San Diego: Academic Press."},{"key":"CR5","doi-asserted-by":"crossref","unstructured":"Beck-Friis, J., Kjellman, B. F., Aperia, B., Unden, F., von Rosen, D., Lunggren, J.-G. and Wetterberg, L. Serum melatonin in relation to clinical variables and a hypothesis of a low melatonin syndrome. Acta Psychiat. Scand. 71:319?330.","DOI":"10.1111\/j.1600-0447.1985.tb02531.x"},{"key":"CR6","doi-asserted-by":"crossref","unstructured":"Brown, R. P., Kocsis, J. H., Caroff, S., Amsterdam, J., Winokur, A., Stokes, P. E. and Frazer, A. Differences in nocturnal melatonin secretion between melancholic depressed patients and control subjects. Am J. Psychiatry, 142:811?816.","DOI":"10.1176\/ajp.142.7.811"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0165-1781(92)90132-M","volume":"43","author":"S. H. Kennedy","year":"1992","unstructured":"Kennedy, S. H., and Brown, G. M. 1992. The effect of chronic antidepressant treatment with adinazolam and desipramine on melatonin output. Psychiatry Res., 43:177?185.","journal-title":"Psychiatry Res."},{"key":"CR8","doi-asserted-by":"crossref","unstructured":"Kennedy, S. H., Garfinkel, P. E., Parienti, V., Costa, D. and Brown, G. M. Changes in melatonin, but not cortisol are associated with depression in eating disorder patients. Arch. Gen. Psychiatry, 46:73?78.","DOI":"10.1001\/archpsyc.1989.01810010075010"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1126\/science.6857245","volume":"22","author":"H. C. Sabelli","year":"1983","unstructured":"Sabelli, H. C., Fawcett, J., Gusovsky, F., Javaid, J., Edwards, J. and Jeffriess, H. 1983. Urinary phenylacetate: A diagnostic test for depression? Science, 22:1187?1188.","journal-title":"Science"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1600-0447.1990.tb01347.x","volume":"82","author":"H. C. Sabelli","year":"1990","unstructured":"Sabelli, H. C., Javaid, J. I., Fawcett, J., Kravitz, H. M. and Wynn, P. 1990. Urinary phenylacetic acid in panic disorder with and without depression. Acta Psychiat. Scand. 82:14?16.","journal-title":"Acta Psychiat. Scand."},{"key":"CR11","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/archpsyc.1982.04290050007002","volume":"39","author":"M. Linnoila","year":"1982","unstructured":"Linnoila, M., Karoum, F. and Potter, W. Z., 1982. Effect of low-dose clorgyline on 24-hour urinary monoamine excretion in patients with rapidly cycling bipolar affective disorder. Arch. Gen. Psychiatry, 39:513?516.","journal-title":"Arch. Gen. Psychiatry"},{"key":"CR12","first-page":"282","volume":"3","author":"D. S. Robinson","year":"1983","unstructured":"Robinson, D. S., Johnson, G. A., Nies, A., Corcella, J., Cooper, T. B., Albright, D. and Howard, D. 1983. Plasma level of catecholamines and dihydroxyphenylglycol during antidepressant drug treatment. J. Clin. Psychopharm. 3:282?287.","journal-title":"J. Clin. Psychopharm."},{"key":"CR13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1471-4159.1979.tb04533.x","volume":"32","author":"L. F. Major","year":"1979","unstructured":"Major, L. F., Murphy, D. L., Lipper, S., and Gordon, E. 1979. Effects of clorgyline and pargyline on deaminated metabolites or norepinephrine, dopamine, and serotonin in human cerebrospinal fluid. J. Neurochem. 32:229?231.","journal-title":"J. Neurochem."},{"key":"CR14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/BF00647833","volume":"324","author":"P. C. Waldmeier","year":"1983","unstructured":"Waldmeier, P. C. and Baumann, P. A. 1983. Effects of CGP 11305A, a new reversible and selective inhibitor of MAOA, on biogenic amine levels and metabolism in the rat brain. Naunyn-Schmiodeberg's Arch Pharmacol. 324:20?26.","journal-title":"Naunyn-Schmiodeberg's Arch Pharmacol."},{"key":"CR15","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archpsyc.1988.01800290091011","volume":"45","author":"T. Walsh","year":"1988","unstructured":"Walsh, T., Gladis, M., Roose, S. P., Stewart, J. W., Stetner, F. and Glassman, A. H. 1988. Phenelzine vs placebo in 50 patients with bulimia. Arch. Gen. Psychiatry. 45:471?475.","journal-title":"Arch. Gen. Psychiatry"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/00004714-198812000-00002","volume":"8","author":"S. H. Kennedy","year":"1988","unstructured":"Kennedy, S. H., Piran, N., Warsh, J. J., Prendergast, P., Mainprize, E., Whynot, C. and Garfinkel, E. 1988. A trial of isocarboxazid in the treatment of bulimia nervosa. J. Clin. Psychopharm. 8:391?396.","journal-title":"J. Clin. Psychopharm."},{"key":"CR17","unstructured":"Kennedy, S. H., Goldbloom, D. S., Ralevski, E., D'Souza, J. and Lofchy, J. Is there a role for selective MAO-inhibitor therapy in bulimia nervosa? A placebo controlled trial of brofaromine. J Clin Psychopharm (in press)."},{"key":"CR18","doi-asserted-by":"crossref","unstructured":"Davis, B. A., Kennedy, S. H., Durden, D. A., D'Souza, J., Goldbloom, D. S. and Boulton, A. A. 1993. The effect of the MAO-A selective inhibitor brofaromine on the plasma and urine concentrations of some biogenic amines and their acidic metabolites in bulimia nervosa. Progr. Neuro-Psychopharmacol. & Biol. Psychiat. (in press).","DOI":"10.1016\/0278-5846(93)90057-Y"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/BF01037949","volume":"25","author":"P. C. Waldmeier","year":"1983","unstructured":"Waldmeier, P. C., Antonin, K. H., Feldtrauer, J. J., Grunenwald, C., Paul, E., Lauber, J. and Bieck, P. 1983. Urinary excretion of O-methylated catecholamines, tyramine and phenylethylamine by volunteers treated with tranylcypromine and CGP 11305 A. Eur. J. Clin. Pharmacol. 25:361?368.","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"CR20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0278-5846(88)90064-4","volume":"12","author":"P. R. Bieck","year":"1988","unstructured":"Bieck, P. R., Antonin, K. H., Balon, R., and Oxenkrug, G. 1988. Effect of brofaromine and pargyline on human plasma melatonin concentrations. Prog. Neuro-psychopharm. Biol. Psychiat. 12:93?101.","journal-title":"Prog. Neuro-psychopharm. Biol. Psychiat."},{"issue":"11S","key":"CR21","first-page":"266S","volume":"29","author":"I. M. Vliet van","year":"1991","unstructured":"van Vliet, I. M., Westenberg, H. and DenBoer, J. 1991. The efficacy of a reversible MAO inhibitor, brofaromine, in panic disorder. Biol. Psychiatry, 29(11S):266S-267S.","journal-title":"Biol. Psychiatry"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0165-1781(86)90067-3","volume":"17","author":"D. L. Murphy","year":"1986","unstructured":"Murphy, D. L., Tamarkin, L., Sunderland, T., Garrick, N. A. and Cohen, R. M. 1986. Human plasma melatonin is elevated during treatment with the monoamine oxidase inhibitors clorgyline and tranylcypromine but not deprenyl. Psychiatry Res. 17:119?127.","journal-title":"Psychiatry Res."},{"key":"CR23","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/BF00431790","volume":"87","author":"S. A. Checkley","year":"1985","unstructured":"Checkley, S. A., Thompson, C., Burton, S., Franey, C. and Arendt, J. 1985. Clinical studies of the effect of (+) and (?) oxaprotiline upon noradrenaline uptake. Psychopharm. 87:116?118.","journal-title":"Psychopharm."},{"key":"CR24","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/BF00442818","volume":"99","author":"J. Fritze","year":"1989","unstructured":"Fritze, J., Laux, G., Sofic, E., Koronakis, P., Schoerlin, M. P., Riederer, P. and Beckmann, H. 1989. Plasma moclobemide and metabolites: lack of correlation with clinical response and biogenic amines. Psychopharmacol. 99:252?256.","journal-title":"Psychopharmacol."}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00975048.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00975048\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00975048","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,5]],"date-time":"2020-04-05T10:52:46Z","timestamp":1586083966000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00975048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,12]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[1993,12]]}},"alternative-id":["BF00975048"],"URL":"https:\/\/doi.org\/10.1007\/bf00975048","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[1993,12]]}}}